Jpmorgan Chase & CO Atai Life Sciences N.V. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Atai Life Sciences N.V. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 16,851 shares of ATAI stock, worth $26,119. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,851
Previous 17,924
5.99%
Holding current value
$26,119
Previous $23,000
17.39%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding ATAI
# of Institutions
89Shares Held
12.5MCall Options Held
77.8KPut Options Held
50.3K-
Morgan Stanley New York, NY3.04MShares$4.71 Million0.0% of portfolio
-
Walleye Capital LLC Plymouth, MN2.26MShares$3.51 Million0.01% of portfolio
-
Black Rock Inc. New York, NY1.31MShares$2.03 Million0.0% of portfolio
-
Brown University719KShares$1.11 Million0.36% of portfolio
-
Round Table Services, LLC704KShares$1.09 Million0.46% of portfolio
About ATAI Life Sciences N.V.
- Ticker ATAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 165,875,008
- Market Cap $257M
- Description
- Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...